JP2013509391A - （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 - Google Patents

（３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 Download PDF

Info

Publication number
JP2013509391A
JP2013509391A JP2012535956A JP2012535956A JP2013509391A JP 2013509391 A JP2013509391 A JP 2013509391A JP 2012535956 A JP2012535956 A JP 2012535956A JP 2012535956 A JP2012535956 A JP 2012535956A JP 2013509391 A JP2013509391 A JP 2013509391A
Authority
JP
Japan
Prior art keywords
compound
crystalline form
dimethyl
pyridinyl
inden
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012535956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509391A5 (https=
Inventor
ベリングハム，リチャード
バスウェル，アンドリュー，マーク
メアリー アイアンモンガー，ヴィクトリア
アーカート，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2013509391A publication Critical patent/JP2013509391A/ja
Publication of JP2013509391A5 publication Critical patent/JP2013509391A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012535956A 2009-10-30 2010-10-28 （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 Pending JP2013509391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25659409P 2009-10-30 2009-10-30
US61/256,594 2009-10-30
PCT/IB2010/003221 WO2011051814A1 (en) 2009-10-30 2010-10-28 Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016000972A Division JP2016106102A (ja) 2009-10-30 2016-01-06 （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態

Publications (2)

Publication Number Publication Date
JP2013509391A true JP2013509391A (ja) 2013-03-14
JP2013509391A5 JP2013509391A5 (https=) 2013-12-12

Family

ID=43921420

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012535956A Pending JP2013509391A (ja) 2009-10-30 2010-10-28 （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態
JP2016000972A Pending JP2016106102A (ja) 2009-10-30 2016-01-06 （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016000972A Pending JP2016106102A (ja) 2009-10-30 2016-01-06 （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態

Country Status (4)

Country Link
US (2) US8716286B2 (https=)
EP (1) EP2493874A1 (https=)
JP (2) JP2013509391A (https=)
WO (1) WO2011051814A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016204127A1 (ja) * 2015-06-15 2016-12-22 バッセル化学株式会社 海中付着生物忌避組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015035223A1 (en) 2013-09-09 2015-03-12 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
ES2737148T3 (es) 2013-12-16 2020-01-10 Peloton Therapeutics Inc Análogos de sulfona y sulfoximina cíclicos y usos de los mismos
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145236A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Hif-2-alpha inhibitor polymorphs
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
JP6933322B2 (ja) 2016-01-04 2021-09-08 メルク セローノ エス．エー． ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形
CN115590849A (zh) 2016-07-21 2023-01-13 奥布赛瓦股份公司（Ch） 促进胚胎植入和预防流产的催产素拮抗剂给药方案
CA3149898A1 (en) 2019-09-03 2021-03-11 Ernest Loumaye Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503534A (ja) * 2004-06-23 2008-02-07 グラクソ　グループ　リミテッド オキシトシン受容体アンタゴニストとしてのピペラジンジオン

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
DE3830096A1 (de) 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
PL342254A1 (en) 1998-01-29 2001-06-04 Aventis Pharm Prod Inc Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound
WO1999047549A1 (en) 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503534A (ja) * 2004-06-23 2008-02-07 グラクソ　グループ　リミテッド オキシトシン受容体アンタゴニストとしてのピペラジンジオン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
長瀬博監訳, 最新 創薬化学 下巻, JPN6008054607, 25 September 1999 (1999-09-25), JP, pages 347 - 365, ISSN: 0002958093 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016204127A1 (ja) * 2015-06-15 2016-12-22 バッセル化学株式会社 海中付着生物忌避組成物

Also Published As

Publication number Publication date
US8815856B2 (en) 2014-08-26
US20140200218A1 (en) 2014-07-17
EP2493874A1 (en) 2012-09-05
JP2016106102A (ja) 2016-06-16
WO2011051814A1 (en) 2011-05-05
US8716286B2 (en) 2014-05-06
US20130109690A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
US8716286B2 (en) Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione
TWI698428B (zh) Mdm2抑制劑之製備方法及結晶型
CN114846006A (zh) 杂环化合物及其制备方法和用途
JP7734700B2 (ja) ベータアドレナリンアゴニストの形態及び組成物
JPWO1998030548A1 (ja) ５−ＨＴ▲下２ｃ▼受容体作用薬及びアミノアルキルインダゾール誘導体
JP2014510139A (ja) 固体形態のｈｉｖ阻害剤
US20160074413A1 (en) Substituted diketopiperazines and their use as oxytocin antagonists
CA3245701A1 (en) SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS
TW201249836A (en) 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof
TW202106680A (zh) Glyt1抑制劑之固體形式
WO2013124385A2 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2016090257A1 (en) Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
CN112119074A (zh) Egfr抑制剂
JP2018537486A (ja) キノロン類似体及びその塩の結晶形
KR20200081359A (ko) 2-(5-(4-(2-모르폴리노에톡시)페닐)피리딘-2-일)-n-벤질아세트아미드의 고체 형태
TWI462915B (zh) 一種組織胺ｈ３受體拮抗劑的新穎富馬酸鹽
KR20080007649A (ko) 피페리딘환을 가지는 인돌 유도체의 결정 및 그의 제조방법
JP2007537229A (ja) ジアルキルオキシインドールの新規なピペラジン誘導体
JP7088411B2 (ja) フェニル酢酸化合物の結晶
CN101175751B (zh) 具有哌啶环的吲哚衍生物的晶体和其制备方法
HK1201837A1 (en) Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor
HK40037665A (en) Egfr inhibitors
OA16618A (en) Novel fumarate salts of a histamine H3 receptor antagonist.
JPWO2006121104A1 (ja) ピペリジン環を有するインドール誘導体の結晶およびその製法
JPWO1994018191A1 (ja) 新規なアミン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150908